Home / Our tests / Breast and Ovarian Cancer (BRCA1 and BRCA2)

Breast and Ovarian Cancer (BRCA1 and BRCA2)

€250.00 EUR €349.00 EUR You save €99.00 EUR
Breast and Ovarian Cancer (BRCA1 and BRCA2)

Breast and Ovarian Cancer (BRCA1 and BRCA2)

€250.00 EUR €349.00 EUR You save €99.00 EUR
description

BRCA1 and BRCA2 are genes called tumor suppressor that work to protect our body against cancer. Their function is to keep breast, ovarian and other cells growing normally.

Everyone has BRCA1 and BRCA2, both men and women.

When either one of these two genes is mutated, people's chance of developing breast and ovarian cancer are greatly increased ( up to 80% for breast cancer, 60% for ovarian cancer).

Early detection of BRCA1 and BRCA2 mutations could allow the development of tailored approach and save your life.

Women with a mutated BRCA1 or BRCA2 gene also have an increased risk of developing ovarian, colon, and pancreatic cancers, as well as melanoma.

Men with an abnormal BRCA1 or BRCA2 have an higher risk of breast cancer, and an higher risk of developing prostate cancer.

About 1 in 300 people carry a BRCA1 mutation, and 1 in 800 carry a BRCA2 mutation.

Next Generation Sequencing (NGS) Technology

Product focus

  • Rapid Turnaround Time

    Only 8-9 weeks to receive accurate tests result via email

  • Certified Genetic Labs

    DNA sequencing provided by Dante Labs network of certified, specialized genetic labs

  • Non Invasive

    No needles. Friendly. Painless. CE approved saliva collection method

  • Next Generation Sequencing

    250X Coverage on BRCA1 and BRCA2 guaranteed

  • specification

    Early Detection

    Early detection of BRCA1 and BRCA2 mutations could allow the development of tailored approach and save your life

  • specification

    Clear Report

    Your results are clear and accurate and can help you make a plan with your healthcare provider to reduce your risk of breast and ovarian cancer

  • specification

    250X

    Next Generation Sequencing with guaranteed 250X coverage on both BRCA1 and BRCA2